Health and Fitness Health and Fitness
Tue, February 26, 2013
Mon, February 25, 2013
Sun, February 24, 2013
Sat, February 23, 2013
Fri, February 22, 2013
Thu, February 21, 2013
[ Thu, Feb 21st 2013 ] - Market Wire
Inorganic Growth of Healthcare
Wed, February 20, 2013
Tue, February 19, 2013
Mon, February 18, 2013
Sun, February 17, 2013
Fri, February 15, 2013
Thu, February 14, 2013
Wed, February 13, 2013
Tue, February 12, 2013
Mon, February 11, 2013
Sun, February 10, 2013
Fri, February 8, 2013
Thu, February 7, 2013
Wed, February 6, 2013
Tue, February 5, 2013

Depomed To Report Fourth Quarter Fiscal Year 2012 Financial Results On Wednesday, February 20, 2013


//health-fitness.news-articles.net/content/2013/ .. ncial-results-on-wednesday-february-20-2013.html
Published in Health and Fitness on Wednesday, February 13th 2013 at 13:15 GMT by Market Wire   Print publication without navigation


Depomed To Report Fourth Quarter Fiscal Year 2012 Financial Results On Wednesday,... -- NEWARK, Calif., Feb. 13, 2013 /PRNewswire/ --

NEWARK, Calif., Feb. 13, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: [ DEPO ]) today announced that it will release fourth quarter fiscal year 2012 financial results after the market closes on Wednesday, February 20, 2013. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm California time to discuss its results.

Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live webcast on the investor relations section of Depomed's website at [ http://www.depomed.com ]. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.

About Depomed
Depomed, Inc. is a specialty pharmaceutical company with three approved and marketed products. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN).  Zipsor ® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults.  Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, [ www.depomed.com ].

CONTACT:
August J. Moretti
Depomed, Inc.
650-462-5900
[ amoretti@depomed.com ]

 

SOURCE Depomed, Inc.



RELATED LINKS
[ http://www.depomed.com ]

Publication Contributing Sources